Evidence map›Paper›PMID 34848944›Full record

ReviewDrug design, development and therapy2021

Therapeutic Effects and Safe Uses of Plant-Derived Polyphenolic Compounds in Cardiovascular Diseases: A Review.

Badriyah Shadid Alotaibi, Munazza Ijaz, Manal Buabeid, Zelal Jaber Kharaba, Hafiza Sidra Yaseen, Ghulam Murtaza

Open access · goldAbstract readReview
In one paragraph

Review in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 85 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Polyphenol-RichPharmaceutics · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Hop (Molecules (Basel, Switzerland) · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Badriyah Shadid AlotaibiDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Munazza IjazInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Manal BuabeidMedical and Bio-Allied Health Sciences Research Centre, Ajman University, Ajman, United Arab Emirates.ORCID 0000-0002-5519-1698
Zelal Jaber KharabaDepartment of Clinical Sciences, College of Pharmacy, Al-Ain University of Science and Technology, Abu Dhabi, United Arab Emirates.
Hafiza Sidra YaseenDepartment of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore, 54000, Pakistan.
Ghulam MurtazaDepartment of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore, 54000, Pakistan.ORCID 0000-0001-5649-5768
COMSATS University Islamabad · PKAjman University · AEAl Ain University · AEPrincess Nourah bint Abdulrahman University · SAUniversity of Lahore · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polyphenols have long been recognized as health-promoting entities, including beneficial effects on cardiovascular disease, but their reputation has been boosted recently following a number of encouraging clinical studies in multiple chronic pathologies, that seem to validate efficacy. Health benefits of polyphenols have been linked to their well-established powerful antioxidant activity. This review aims to provide comprehensive and up-to-date knowledge on the current therapeutic status of polyphenols having sufficient heed towards the treatment of cardiovascular diseases. Furthermore, data about the safety profile of highly efficacious polyphenols has also been investigated to further enhance their role in cardiac abnormalities. Evidence is presented to support the action of phenolic derivatives against cardiovascular pathologies by following receptors and signaling pathways which ultimately cause changes in endogenous antioxidant, antiplatelet, vasodilatory, and anti-inflammatory activities. In addition, in vitro antioxidant and pre-clinical and clinical experiments on anti-inflammatory as well as immunomodulatory attributes of polyphenols have revealed their role as cardioprotective agents. However, an obvious shortage of in vivo studies related to dose selection and toxicity of polyphenols makes these compounds a suitable target for clinical investigations. Further studies are needed for the development of safe and potent herbal products against cardiovascular diseases. The novelty of this review is to provide comprehensive knowledge on polyphenols safety and their health claims. It will help researchers to identify those moieties which likely exert protective and therapeutic effects towards cardiovascular diseases.

Indexed as

Cardiotonic AgentsCardiovascular DiseasesHumansPolyphenolsCardiotonic AgentsPolyphenolsantioxidantcardioprotectivecardiovascular diseasesclinical trialspolyphenols

Identifiers

PMID34848944
PMCPMC8619826
OpenAlexW3217080221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.